Trial · NCT02220894
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50% | Pembrolizumab | 20.0 | 95% Confidence Interval 15.9 to 24.2 | Months | |
| Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50% | Chemotherapy (SOC Treatment) | 12.2 | 95% Confidence Interval 10.4 to 14.6 | Months | |
| Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20% | Pembrolizumab | 18.0 | 95% Confidence Interval 15.4 to 21.9 | Months | |
| Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20% | Chemotherapy (SOC Treatment) | 13.0 | 95% Confidence Interval 11.6 to 15.3 | Months | |
| Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1% | Pembrolizumab | 16.4 | 95% Confidence Interval 14.0 to 19.7 | Months | |
| Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1% | Chemotherapy (SOC Treatment) | 12.1 | 95% Confidence Interval 11.3 to 13.3 | Months | |
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% | Pembrolizumab | 6.5 | 95% Confidence Interval 5.9 to 8.5 | Months | |
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% | Chemotherapy (SOC Treatment) | 6.4 | 95% Confidence Interval 6.2 to 7.2 | Months | |
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% | Pembrolizumab | 6.2 | 95% Confidence Interval 5.1 to 7.4 | Months | |
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% | Chemotherapy (SOC Treatment) | 6.7 | 95% Confidence Interval 6.3 to 8.0 | Months | |
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% | Pembrolizumab | 5.4 | 95% Confidence Interval 4.3 to 6.2 | Months | |
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% | Chemotherapy (SOC Treatment) | 6.6 | 95% Confidence Interval 6.3 to 7.3 | Months | |
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% | Pembrolizumab | 39.1 | 95% Confidence Interval 33.6 to 44.9 | Percentage of participants | |
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% | Chemotherapy (SOC Treatment) | 32.0 | 95% Confidence Interval 26.8 to 37.6 | Percentage of participants | |
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% | Pembrolizumab | 33.2 | 95% Confidence Interval 28.6 to 37.9 | Percentage of participants | |
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% | Chemotherapy (SOC Treatment) | 28.9 | 95% Confidence Interval 24.5 to 33.6 | Percentage of participants | |
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% | Pembrolizumab | 27.2 | 95% Confidence Interval 23.7 to 30.8 | Percentage of participants | |
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% | Chemotherapy (SOC Treatment) | 26.5 | 95% Confidence Interval 23.1 to 30.1 | Percentage of participants | |
| Number of Participants Who Experienced At Least One Adverse Event (AE) | Pembrolizumab | 608 | Participants | ||
| Number of Participants Who Experienced At Least One Adverse Event (AE) | Chemotherapy (SOC Treatment) | 606 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02220894/results